These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [Heparins, antivitamins K. Principles and rules of use. Posology of non-fractionated heparins]. Delsart D; Chambefort V; Decousus H Rev Prat; 2001 Sep; 51(13):1489-97. PubMed ID: 11601082 [No Abstract] [Full Text] [Related]
28. Use of low-molecular-weight heparins in the treatment and secondary prevention of cancer-associated thrombosis. Grande C; Caparro M Semin Oncol Nurs; 2005 Nov; 21(4 Suppl 1):41-9. PubMed ID: 16360897 [TBL] [Abstract][Full Text] [Related]
29. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Haas S Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477 [TBL] [Abstract][Full Text] [Related]
31. Development in anticoagulant therapy. van Doormaal FF; Büller HR; Middeldorp S Crit Rev Oncol Hematol; 2008 May; 66(2):145-54. PubMed ID: 18032061 [TBL] [Abstract][Full Text] [Related]
32. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174 [TBL] [Abstract][Full Text] [Related]
33. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin. Martínez-González J; Rodríguez C Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295 [TBL] [Abstract][Full Text] [Related]
34. Laboratory monitoring of anticoagulation: where do we stand? Tripodi A; van den Besselaar A Semin Thromb Hemost; 2009 Feb; 35(1):34-41. PubMed ID: 19308891 [TBL] [Abstract][Full Text] [Related]
35. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421 [TBL] [Abstract][Full Text] [Related]
36. Low-molecular-weight heparin for initial treatment of venous thromboembolism. Brewer D Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683 [No Abstract] [Full Text] [Related]
38. Emerging anticoagulants: mechanism of action and future potential. Klement P; Rak J Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459 [TBL] [Abstract][Full Text] [Related]
39. Antithrombotic therapy and survival in cancer patients. Kakkar AK Best Pract Res Clin Haematol; 2009 Mar; 22(1):147-51. PubMed ID: 19285281 [TBL] [Abstract][Full Text] [Related]
40. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of deep venous thrombosis. Hirsh J Semin Hematol; 1997 Oct; 34(4 Suppl 4):20-5. PubMed ID: 9399406 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]